Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00728780
Recruitment Status : Completed
First Posted : August 6, 2008
Last Update Posted : September 28, 2012
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this study is to compare the pharmacokinetics of ABT-335 and rosuvastatin from ABT-143 relative to that from the co-administration of ABT-335 and rosuvastatin.

Condition or disease Intervention/treatment Phase
Adverse Events Pharmacokinetic Variables Drug: ABT-143 Drug: ABT-335 and rosuvastatin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : August 2008
Actual Primary Completion Date : September 2008

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: A
ABT-143 15/135mg
Drug: ABT-143
once

Active Comparator: B
ABT-335 135mg and rosuvastatin 15mg
Drug: ABT-335 and rosuvastatin
once




Primary Outcome Measures :
  1. Adverse events and safety laboratory assessments [ Time Frame: 7 days ]
  2. Pharmacokinetic parameters [ Time Frame: 7 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Signed informed consent
  • Condition of good health

Exclusion Criteria:

  • Currently enrolled in another study
  • Females who are pregnant or breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00728780


Locations
Layout table for location information
United States, Indiana
Site Reference ID/Investigator# 11101
Evansville, Indiana, United States, 47710
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Study Director: Torbjörn Lundström AstraZeneca
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00728780    
Other Study ID Numbers: M10-586
First Posted: August 6, 2008    Key Record Dates
Last Update Posted: September 28, 2012
Last Verified: September 2012
Keywords provided by AstraZeneca:
Adverse events
Pharmacokinetic variables
Additional relevant MeSH terms:
Layout table for MeSH terms
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors